 | Third Annual Multidisciplinary Symposium: Improving Clinical Outcomes in Genitourinary Malignancy
30 October - 1 November 2008 - Paris, France
Hotel Le Méridien Etoile
Paris, France
|
|---|
Activity Overview | PROGRAM CO-CHAIRS:
Cora Sternberg, MD, FACP
Fred Saad, MD, FRCS
EDUCATIONAL OBJECTIVES
Following this meeting, participants will be able to demonstrate improvements in:
- Explain and compare how emerging therapies and regimens are changing the management of prostate and renal cancer
- Identify how to integrate targeted therapies into clinical practice
- Distinguish the differences in surgical considerations for renal cancer patients
- Compare clinical trials data and endpoints to establish the best supportive care for patients with prostate and renal cancer
- Discuss the latest preclinical data supporting the role of bisphosphonates for prostate cancer
- Review the role of surgery and irradiation for the patient with high risk prostate cancer
TARGET AUDIENCE
300 European Urologists and Medical Oncologists
|
Agenda |
|
Thursday, 30 October 2008
|
|
Afternoon/Evening Arrivals
|
|
Welcome Reception
|
|
Friday, 31 October 2008
|
|
08.30-08.45
|
Welcome-Co-chairs
Introduction and Demographics
|
Cora Sternberg, MD, FACP
Fred Saad, MD, FRCS
Lee Lokey, MD
|
|
08.45-12.45
|
Renal Cell Carcinoma
|
Moderators:
Tim Eisen, MD, PhD, FRCP
Peter Mulders, MD, PhD
|
|
08.45-09.20
|
Surgical Considerations: Laparoscopic Versus Open Procedures, Partial Nephrectomy
|
Inderbir Gill, MD, M.Ch
|
|
09.20-09.45
|
Molecular Targeted Therapy for Advanced Disease
|
Cora Sternberg, MD, FACP
|
|
09:45-10.10
|
Sequencing Targeted Therapies & Best Options for Second-Line Treatment
|
Alain Ravaud, MD, PhD
|
|
10.10-10.30
|
The Role of Bisphosphonates in RCC
|
Peter Mulders, MD, PhD
|
|
10.30-10.50
|
Break
|
|
10.50-11.25
|
The Role of Surgery in Metastatic RCC in the Era of Molecular Targeted Therapies
|
Christopher Wood, MD, FACS
|
|
11.25-11.50
|
Adjuvant & Neoadjuvant Strategies in the Era of Targeted Therapy
|
Tim Eisen, MD, PhD, FRCP
|
|
11.50-12.45
|
Expert PracticeSM in RCC: Interactive Clinical Cases
|
Faculty Panel:
Tim Eisen, MD, PhD, FRCP
Inderbir Gill, MD, M.Ch
Peter Mulders, MD, PhD
Alain Ravaud, MD, PhD
Fred Saad, MD, FRCS
Cora Sternberg, MD, FACP
Christopher Wood, MD, FACS
|
|
12.45-13.45
|
Lunch
|
|
13.45-17.00
|
Advanced Prostate Cancer
|
Moderators:
Mario Eisenberger, MD, PhD
Karim Fizazi, MD, PhD
|
|
13.45-14.10
|
HRPC-Definition and Role of Chemotherapy
|
Mario Eisenberger, MD, PhD
|
|
14.10-14.35
|
Current Status of Endocrine Therapy for Advanced Disease
|
Bertrand Tombal, MD, PhD
|
|
14.35-15.00
|
Current Clinical Trials and Future Directions
|
Cora Sternberg, MD, FACP
|
|
15.00-15.25
|
Role of Bisphosphonates in HRPC
|
Fred Saad, MD, FRCS
|
|
15.25-15.45
|
Break
|
|
15.45-16.45
|
Expert PracticeSM in Advanced PC: Interactive Clinical Cases
|
Faculty Panel:
Mario Eisenberger, MD, PhD
Karim Fizazi, MD, PhD
Nicholas James, MD, PhD
Fred Saad, MD, FRCS
Cora Sternberg, MD, FACP
Bertrand Tombal, MD, PhD
|
|
16.45-17.00
|
Concluding Remarks and Symposium Summary
|
Cora Sternberg, MD, FACP
Fred Saad, MD, FRCS
|
|
Saturday, 1 November 2008
|
|
08.30-11.40
|
High Risk Prostate Cancer
|
Moderators:
Fred Saad, MD, FRCS
Per-Anders Abrahamsson, MD, PhD
|
|
08.30-08.55
|
Identifying the “High Risk” Patient
|
Per-Anders Abrahamsson, MD, PhD
|
|
08.55-09.20
|
Surgical Management
|
Fred Saad, MD, FRCS
|
|
09.20-09.45
|
Optimizing the Role of Irradiation in the High Risk Patient
|
Nicholas James, MD, PhD
|
|
09.45-10.10
|
Optimal Use of Neoadjuvant and Adjuvant Therapy
|
Mario Eisenberger, MD, PhD
|
|
10.10-10.30
|
Break
|
|
10.30-10.55
|
Clinical Trials for the High Risk Patient
|
Karim Fizazi, MD, PhD
|
|
10.55-11.50
|
Expert PracticeSM in High Risk PC: Interactive Clinical Cases
|
Faculty Panel:
Per-Anders Abrahamsson, MD, PhD
Mario Eisenberger, MD, PhD
Karim Fizazi, MD, PhD
Nicholas James, MD, PhD
Fred Saad, MD, FRCS
Cora Sternberg, MD, FACP
|
|
11.50-12.00
|
Symposium Summary
|
Cora Sternberg, MD, FACP
Fred Saad, MD, FRCS
|
|
|
